A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent

Condition:   Multiple Myeloma Intervention:   Drug: Daratumumab Sponsor:   Johnson & Johnson Private Limited Not yet recruiting

Source: ClinicalTrials.gov - December 7, 2018 Category: Research Source Type: clinical trials